Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.79 USD
-0.04 (-1.41%)
Updated Jul 22, 2024 01:16 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLO 2.79 -0.04(-1.41%)
Will ALLO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Other News for ALLO
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Allogene Therapeutics initiates Phase 2 cema-cel trial